Drug Profile
OPK 88004
Alternative Names: LY-2452473; OPK-88004; TT701Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Brigham and Women's Hospital; Dana-Farber Cancer Institute; OPKO Health
- Class Antineoplastics; Erectile dysfunction therapies; Small molecules
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Benign prostatic hyperplasia; Erectile dysfunction; Prostate cancer
Most Recent Events
- 08 Sep 2021 Phase II development is ongoing in Prostrate cancer in USA (OPKO pipeline, September 2021)
- 11 Nov 2019 Dana-Farber Cancer Institute completes a phase II trial in Prostate cancer in USA (PO) (NCT02499497)
- 03 Jul 2019 Transition Therapeutics and OPKO Health terminate a phase II trial in Benign prostatic hyperplasia in USA (NCT03297398)